Selective Bibliography of Dr. Larry K. Keefer
Lab of Comparative Carcinogenesis, NCI

"Nitric Oxide and Immune System Function"
Wednesday, May 6, 2009

1. Qu W, Liu J, Dill AL, Saavedra JE, Keefer LK, Waalkes MP
V-PROLI/NO, a nitric oxide donor prodrug, protects liver cells from arsenic-induced toxicity
CANCER SCIENCE 100 (3):382-388 Mar 2009

2. Shami PJ, Maciag AE, Eddington JK, Udupi V, Kosak KM, Saavedra JE, Keefer LK
JS-K, an arylating nitric oxide (NO) donor, has synergistic anti-leukemic activity with cytarabine (ARA-C)
LEUKEMIA RESEARCH [Epub ahead of print] Feb 2 2009

3. Kitagaki J, Yang Y, Saavedra JE, Colburn NH, Keefer LK, Perantoni AO
Nitric oxide prodrug JS-K inhibits ubiquitin E1 and kills tumor cells retaining wild-type p53
ONCOGENE 28 (4):619-624 Jan 29 2009

4. Andrei D, Maciag AE, Chakrapani H, Citro ML, Keefer LK, Saavedra JE
Aryl bis(diazeniumdiolates): potent inducers of S-glutathionylation of cellular proteins and their in vitro antiproliferative activities
JOURNAL OF MEDICINAL CHEMISTRY 51 (24):7944-7952 Dec 25 2008

5. Ahanchi SS, Varu VN, Tsihlis ND, Martinez J, Pearce CG, Kapadia MR, Jiang Q, Saavedra JE, Keefer LK, Hrabie JA, Kibbe MR
Heightened efficacy of nitric oxide-based therapies in type II diabetes mellitus and metabolic syndrome
AMERICAN JOURNAL OF PHYSIOLOGY HEART AND CIRCULATORY PHYSIOLOGY 295 (6):H2388-H2398 Dec 2008

6. Chakrapani H, Maciag AE, Citro ML, Keefer LK, Saavedra JE
Cell-permeable esters of diazeniumdiolate-based nitric oxide prodrugs
ORGANIC LETTERS 10 (22):5155-5158 Nov 20 2008

7. Chakrapani H, Kalathur RC, Maciag AE, Citro ML, Ji X, Keefer LK, Saavedra JE
Synthesis, mechanistic studies, and anti-proliferative activity of glutathione/glutathione S-transferase-activated nitric oxide prodrugs
BIOORGANIC & MEDICINAL CHEMISTRY 16 (22):9764-9771 Nov 15 2008

8. Valdez CA, Saavedra JE, Showalter BM, Davies KM, Wilde TC, Citro ML, Barchi JJ, Jr., Deschamps JR, Parrish D, El-Gayar S, Schleicher U, Bogdan C, Keefer LK
Hydrolytic reactivity trends among potential prodrugs of the O2-glycosylated diazeniumdiolate family. Targeting nitric oxide to macrophages for antileishmanial activity
JOURNAL OF MEDICINAL CHEMISTRY 51 (13):3961-3970 Jul 10 2008

9. Simeone AM, McMurtry V, Nieves-Alicea R, Saavedra JE, Keefer LK, Johnson MM, Tari AM
TIMP-2 mediates the anti-invasive effects of the nitric oxide-releasing prodrug JS-K in breast cancer cells
BREAST CANCER RESEARCH 10 (3):R44 2008

10. Velazquez CA, Chen QH, Citro ML, Keefer LK, Knaus EE
Second-generation aspirin and indomethacin prodrugs possessing an O(2)-(acetoxymethyl)-1-(2-carboxypyrrolidin-1-yl)diazenium-1,2-diolate nitric oxide donor moiety: design, synthesis, biological evaluation, and nitric oxide release studies
JOURNAL OF MEDICINAL CHEMISTRY 51 (6):1954-1961 Mar 27 2008

Created 3/31/09